Targeting Endoplasmic Reticulum Stress with Tauroursodeoxycholic Acid: A Potential Therapeutic Strategy for Allergic Airway Diseases

Allergic airway diseases (AADs) such as asthma and allergic rhinitis impose a heavy global health burden, characterized by chronic airway inflammation, airway hyperresponsiveness, and structural remodeling. Endoplasmic reticulum (ER) stress has been increasingly identified as a key driver of AAD pathogenesis. As a well-characterized chemical chaperone, tauroursodeoxycholic acid (TUDCA) exhibits promising therapeutic potential for AADs by regulating immunity, relieving inflammation, and reversing airway pathological lesions.

This review summarizes how ER stress drives AAD development and progression of AADs and details the molecular mechanisms underlying the therapeutic effects of TUDCA by targeting ER stress-related unfolded protein response signaling pathways. Additionally, it highlights preclinical evidence supporting the efficacy of TUDCA and discusses the prospects and challenges associated with its clinical translation.

ER stress is a key pathogenic factor in AADs; TUDCA can target ER stress-related signaling pathways to exert therapeutic effects on AADs; preclinical studies confirm the efficacy of TUDCA, and its clinical translation may provide a novel ER stress-targeted strategy to optimize AAD management and improve patient outcomes.